Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 6/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | HTR3E | A5X5Y0 | 4/20 | 0.41 |
| ▸ | HTR3B | O95264 | 4/20 | 0.41 |
| ▸ | HTR3A | P46098 | 4/20 | 0.41 |
| ▸ | HTR3D | Q70Z44 | 4/20 | 0.41 |
| ▸ | HTR3C | Q8WXA8 | 4/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | PLD1 | Q13393 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1678359 | 0.84 | CHRNB2 (0.40) | CHRM2CHRM1HRH1USP2SMN1; SMN2 | |
| SCHEMBL5551088 | 0.83 | ADRB1 (0.43) | ADRB1CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL13992726 | 0.80 | ADRB1 (0.36) | ADRB1CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL16749981 | 0.77 | ADRB1 (0.35) | ADRB1CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL6423838 | 0.72 | CHRM2 (0.31) | ADRB1CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL28620324 | 0.65 | — | — | |
| SCHEMBL8064202 | 0.63 | ALDH1A1 (0.41) | ALDH1A1LMNASMN1; SMN2TDP1KDM4E | |
| SCHEMBL1843440 | 0.63 | CXCR4 (0.77) | CHRM2CHRM4CHRM1CHRM3SIGMAR1 | |
| SCHEMBL15748040 | 0.63 | HRH1 (0.61) | ADRB1CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL1229731 | 0.63 | HRH1 (0.85) | ADRB1ALDH1A1HTR3EHTR3BHTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025087229-A1 | LIGAND COMPOUND OF QUINOLINE STRUCTURE, RADIOACTIVE OR NON-RADIOACTIVE MARKER, AND USE | 四川科伦博泰生物医药股份有限公司 | 2025-05-01 | — | — | WO | disclosed |
| WO-2025087466-A2 | LIGAND COMPOUND OF QUINOLINE STRUCTURE, AND RADIOACTIVE OR NON-RADIOACTIVE MARKER THEREOF AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2025-05-01 | — | — | WO | disclosed |
| US-7928096-B2 | Polydiazeniumdiolated cyclic polyamines with polyphasic nitric oxide release and related compounds, compositions comprising same and methods of using same | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-04-19 | — | — | US | disclosed |
| US-20090068248-A1 | POLYDIAZENIUMDIOLATED CYCLIC POLYAMINES WITH POLYPHASIC NITRIC OXIDE RELEASE AND RELATED COMPOUNDS, COMPOSITIONS COMPRISING SAME AND METHODS OF USING SAME | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HE (US) | 2009-03-12 | — | — | US | disclosed |
| US-7468435-B2 | Polydiazeniumdiolated cyclic polyamines with polyphasic nitric oxide release and related compounds, compositions comprising same and methods of using same | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2008-12-23 | — | — | US | disclosed |
| US-20050148566-A1 | Polydiazeniumdiolated cyclic polyamines with polyphasic nitric oxide release and related compounds, compositions comprising same and methods of using same | THE GOVERNMENT OF THE USA, AS REP. BY THE SECRETARY, DEPT. OF HEALTH & HUMAN SERVICES (US) | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090068248-A1 | POLYDIAZENIUMDIOLATED CYCLIC POLYAMINES WITH POLYPHASIC NITRIC OXIDE RELEASE AND RELATED COMPOUNDS, COMPOSITIONS COMPRISING SAME AND METHODS OF USING SAME | NOS2, ARG2, NOS1 | ADRB1 1787/4885CHRM2 15/4885CHRM4 287/4885 |
| US-20050148566-A1 | Polydiazeniumdiolated cyclic polyamines with polyphasic nitric oxide release and related compounds, compositions comprising same and methods of using same | NOS2, ARG2, NOS1 | ADRB1 1787/4885CHRM2 15/4885CHRM4 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.